← Back to Search

Virus Therapy

SGN-ALPV for Cancer

Phase 1
Waitlist Available
Research Sponsored by Seagen Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
For specific tumor types in Part C, participants must meet additional criteria related to disease progression and prior therapies
Participants must have histologically or cytologically confirmed metastatic or unresectable solid tumor types as specified for each study part
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 2 years
Awards & highlights
No Placebo-Only Group

Study Summary

This trial will test the safety of a new drug, SGN-ALPV, for people with solid tumors. It will also study the drug's side effects. The trial will have three parts, testing different doses to find the most effective and safe amount.

Who is the study for?
This trial is for adults with advanced solid tumors like stomach, cervical, testicular cancers and more. These tumors must be metastatic or unresectable. Participants need confirmed diagnoses and may require biopsies. They should not have had certain recent cancers or treatments that could interfere with the study.Check my eligibility
What is being tested?
SGN-ALPV is being tested to determine its safety and effectiveness in treating various solid tumor cancers. The trial has three parts: Parts A and B will establish the proper dose; Part C will assess how safe it is at that dose and if it helps treat cancer.See study design
What are the potential side effects?
While specific side effects of SGN-ALPV are not listed, they can include any unintended effect on your body besides treating the disease. This might involve reactions at the drug injection site, general discomforts like nausea or fatigue, or other organ-specific issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
For certain types of tumors in Part C, you need to have specific disease progression and previous treatments to be eligible.
Select...
Participants must have a confirmed advanced or inoperable solid tumor.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with DLTs by dose level
Number of participants with adverse events (AEs)
Number of participants with dose-limiting toxicities (DLTs)
+1 more
Secondary outcome measures
Apparent terminal half-life (t1/2)
Area under the concentration-time curve (AUC)
CA-125 response rate according to Gynecological Cancer Intergroup (GCIG) criteria (subjects with ovarian cancer only)
+9 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: SGN-ALPVExperimental Treatment1 Intervention
SGN-ALPV monotherapy

Find a Location

Who is running the clinical trial?

Seagen Inc.Lead Sponsor
206 Previous Clinical Trials
69,296 Total Patients Enrolled
Suzanne McGoldrick, MDStudy DirectorSeagen Inc.
1 Previous Clinical Trials
111 Total Patients Enrolled

Media Library

SGN-ALPV (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05229900 — Phase 1
Gastroesophageal Junction Cancer Research Study Groups: SGN-ALPV
Gastroesophageal Junction Cancer Clinical Trial 2023: SGN-ALPV Highlights & Side Effects. Trial Name: NCT05229900 — Phase 1
SGN-ALPV (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05229900 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is SGN-ALPV considered a secure treatment for individuals?

"As this is a Phase 1 trial, there are only limited safety and efficacy data available for SGN-ALPV. As such, our team at Power assessed the drug's safety with a score of 1."

Answered by AI

Are there numerous centers conducting this trial in Canada?

"The current roster of 7 clinical trial sites includes Oklahoma City, Fairfax and Fresno. If you choose to enrol in the study, it is recommended that you select a clinic at close proximity to minimize transportation needs."

Answered by AI

How many individuals have enrolled in this trial thus far?

"Affirmative. Information available through clinicaltrials.gov verifies that the trial, initially posted on April 21st 2022, is actively recruiting. A total of 285 patients are necessary to be obtained across 7 different sites."

Answered by AI

Who else is applying?

How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
~15 spots leftby Feb 2025